Anhui Anke Biotechnology (Group) Co., Ltd. (300009.SZ)
- Previous Close
9.55 - Open
9.81 - Bid 9.85 x --
- Ask 9.86 x --
- Day's Range
9.51 - 9.97 - 52 Week Range
7.56 - 11.55 - Volume
21,983,190 - Avg. Volume
15,802,275 - Market Cap (intraday)
16.517B - Beta (5Y Monthly) 0.52
- PE Ratio (TTM)
19.31 - EPS (TTM)
0.51 - Earnings Date --
- Forward Dividend & Yield 0.25 (2.62%)
- Ex-Dividend Date May 19, 2023
- 1y Target Est
19.54
Anhui Anke Biotechnology (Group) Co., Ltd. develops, produces, and markets pharmaceutical products in China and internationally. The company offers recombinant human growth hormone for injection under the Ansomone name; and recombinant human interferon alpha 2b lyophilized powder, liquid, and prefilled syringe for injection, as well as recombinant human interferon alpha 2b cream, eye drop, and suppository under the Anterferon name. It provides anti-sperm antibody, semen leukocyte peroxidase staining, one-time semen processing, sperm hypo-osmotic staining, sperm life detection, sperm staining detection, sperm acrosin detection, sperm DNA fragmentation staining, and leptin and immunohistochemical diagnostic kits. In addition, the company offers adhesive plasters, oral solutions, topical preparations, and ointments; peptide APIs; beauty care and anti-aging products; and synthetic drugs in the form of oral powders, dripping pills, and tablets and capsules. Further, it provides autosomal, sex chromosome, autosomal and sex chromosome combination, and other kits, as well as paternity testing set packages; tumor biological immunotherapy products; and DNA testing professional services. Anhui Anke Biotechnology (Group) Co., Ltd. was founded in 2000 and is based in Hefei, China.
www.ankebio.comRelated News
Performance Overview: 300009.SZ
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 300009.SZ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 300009.SZ
Valuation Measures
Market Cap
16.01B
Enterprise Value
14.61B
Trailing P/E
18.73
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.54
Price/Book (mrq)
4.28
Enterprise Value/Revenue
5.10
Enterprise Value/EBITDA
14.29
Financial Highlights
Profitability and Income Statement
Profit Margin
29.56%
Return on Assets (ttm)
12.39%
Return on Equity (ttm)
23.41%
Revenue (ttm)
2.87B
Net Income Avi to Common (ttm)
847.23M
Diluted EPS (ttm)
0.51
Balance Sheet and Cash Flow
Total Cash (mrq)
1.46B
Total Debt/Equity (mrq)
1.44%
Levered Free Cash Flow (ttm)
591.82M
Research Analysis: 300009.SZ
Company Insights: 300009.SZ
300009.SZ does not have Company Insights